Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

By J. Vos, Bharat Burman, Swati Jain, C. Fitzgerald, E. Sherman, L. Dunn, J. Fetten, L. Michel, Anuja Kriplani, K. Ng and 19 more. 2023

Subfields: Oncology, Pharmacology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “Recurrent or metastatic SGCs remain challenging to treat, with limited curative options and no disease-specific FDA-approved therapies [9, 10].”
• Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review) (2025, unknown): “Another study of ACC patients, where nivolumab was combined with the CTLA‑4 inhibitor ipilimumab, reported an even lower overall response rate compared with nivolumab alone, at ~6% (119).”